|
|
Blood, 15 August 2006, Vol. 108, No. 4, pp. 1284-1290.
Prepublished online as a Blood First Edition Paper on April 25, 2006; DOI 10.1182/blood-2005-12-4821.
 Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells
Ofer Levy,
Eugénie E. Suter,
Richard L. Miller, and
Michael R. Wessels
From the Division of Infectious Diseases, Children's Hospital and Harvard Medical School, Boston, MA; and 3M Pharmaceuticals, St Paul, MN.
Newborns are prone to microbial infection and have poor memory responses to multiple antigens. We have previously shown that human neonatal blood monocytes exhibit impaired TNF- responses to most known TLR agonists, including the pure TLR7 agonist imiquimod. Surprisingly, however, neonatal TNF- responses to the imiquimod congener R-848 (TLR 7/8) were fully intact. We now show that TLR8 agonists, including R-848 (TLR7/8), the imidazoquinoline congeners 3M-003 (TLR7/8) and 3M-002 (TLR8), as well as single-stranded viral RNAs (TLR8) induced robust production of the Th1-polarizing cytokines TNF- and IL-12 from neonatal antigen-presenting cells (APCs) that substantially exceeds responses induced by TLR-2, -4, or -7 (alone) agonists. TLR8 agonists also effectively induced up-regulation of the costimulatory molecule CD40 on neonatal and adult myeloid dendritic cells (DCs). The strong activity of TLR8 agonists correlates with their induction of p38 MAP kinase phosphorylation and with degradation of I B- in both neonatal and adult monocytes. We conclude that TLR8 agonists are uniquely efficacious in activating costimulatory responses in neonatal APCs and suggest that these agents are promising candidate adjuvants for enhancing immune responses in human newborns.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Larange, D. Antonios, M. Pallardy, and S. Kerdine-Romer
TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation
J. Leukoc. Biol.,
April 1, 2009;
85(4):
673 - 683.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Qu, V. A. Nguyen, M. Merad, and G. J. Randolph
MHC Class I/Peptide Transfer between Dendritic Cells Overcomes Poor Cross-Presentation by Monocyte-Derived APCs That Engulf Dying Cells
J. Immunol.,
March 15, 2009;
182(6):
3650 - 3659.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Wynn, P. O. Scumpia, R. D. Winfield, M. J. Delano, K. Kelly-Scumpia, T. Barker, R. Ungaro, O. Levy, and L. L. Moldawer
Defective innate immunity predisposes murine neonates to poor sepsis outcome but is reversed by TLR agonists
Blood,
September 1, 2008;
112(5):
1750 - 1758.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Marin-Esteban, M. Abdul, D. Charron, A. Haziot, and N. Mooney
Dendritic Cells Differentiated in the Presence of a Single-Stranded Viral RNA Sequence Conserve Their Ability To Activate CD4 T Lymphocytes but Lose Their Capacity for Th1 Polarization
Clin. Vaccine Immunol.,
June 1, 2008;
15(6):
954 - 962.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Meier, G. Alter, N. Frahm, H. Sidhu, B. Li, A. Bagchi, N. Teigen, H. Streeck, H.-J. Stellbrink, J. Hellman, et al.
MyD88-Dependent Immune Activation Mediated by Human Immunodeficiency Virus Type 1-Encoded Toll-Like Receptor Ligands
J. Virol.,
August 1, 2007;
81(15):
8180 - 8191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. E. Walker and D. R. Goldstein
Neonatal B Cells Suppress Innate Toll-Like Receptor Immune Responses and Modulate Alloimmunity
J. Immunol.,
August 1, 2007;
179(3):
1700 - 1710.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Echeverry, K. Schesser, and B. Adkins
Murine Neonates Are Highly Resistant to Yersinia enterocolitica following Orogastric Exposure
Infect. Immun.,
May 1, 2007;
75(5):
2234 - 2243.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Levy
Bruton tyrosine kinase (Btk): key for signaling via Toll-like receptor 8
Blood,
March 15, 2007;
109(6):
2273 - 2274.
[Full Text]
[PDF]
|
|
|
|
|
